Literature DB >> 7635569

Comparison of solutol HS 15, Cremophor EL and novel ethoxylated fatty acid surfactants as multidrug resistance modification agents.

L E Buckingham1, M Balasubramanian, R M Emanuele, K E Clodfelter, J S Coon.   

Abstract

Some well-known fatty acid ester surfactants, e.g., Cremophor EL and Solutol HS 15, are modulators of multidrug resistance in vitro and in vivo. Because they are polydisperse, and their active component(s) have not been identified, the therapeutic potential of such surfactants is unclear. To better define the active components of Solutol HS 15 and to make more potent surfactant multidrug resistance modulators, highly purified C-18 fatty acids were esterified with ethylene oxide at 5-200 molar ratios. Unexpectedly, ethylene oxide esters of pure 12-hydroxy stearic acid, the major components of Solutol HS 15, displayed negligible resistance modification activity compared with Solutol HS 15 itself or to stearic and oleic acid esters synthesized under identical conditions. Since oleic acid esters appeared to have good activity, a series of these compounds was prepared to determine the optimal ethylene oxide/fatty acid ratio. The optimal ratio was found to be 20 mole ethylene oxide: I mole fatty acid, with a steep decline in activity for products made with ratios above and below the optimum. The most active oleic acid ester, designated CRL 1337, was 8.4-fold as potent as Solutol HS 15 and over 19-fold as potent as Cremophor EL in promoting rhodamine 123 accumulation in multidrug-resistant KB 8-5-11 cells in vitro. Our results show that the structure of the hydrophobic domain (fatty acid) of surfactants as well as its hydrophile-lipophile balance are critical in determining the potency of surfactants as reversing agents.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7635569     DOI: 10.1002/ijc.2910620413

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (-/-) CF-1 mice.

Authors:  Manuela Pereira de Oliveira; Emmanuel Garcion; Nicolas Venisse; Jean-Pierre Benoit; William Couet; Jean-Christophe Olivier
Journal:  Pharm Res       Date:  2005-11       Impact factor: 4.200

2.  Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS).

Authors:  J M Dintaman; J A Silverman
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

3.  Interaction of paclitaxel (Taxol) and irradiation. In-vitro differences between tumor and fibroblastic cells.

Authors:  N Cordes; L Plasswilm; R Sauer
Journal:  Strahlenther Onkol       Date:  1999-04       Impact factor: 3.621

4.  CriticalSorb™ promotes permeation of flux markers across isolated rat intestinal mucosae and Caco-2 monolayers.

Authors:  D J Brayden; V A Bzik; A L Lewis; L Illum
Journal:  Pharm Res       Date:  2012-05-26       Impact factor: 4.200

5.  Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules.

Authors:  Sandra Peltier; Jean-Michel Oger; Frédéric Lagarce; William Couet; Jean-Pierre Benoît
Journal:  Pharm Res       Date:  2006-05-25       Impact factor: 4.200

Review 6.  Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities.

Authors:  Ameya R Kirtane; Stephen M Kalscheuer; Jayanth Panyam
Journal:  Adv Drug Deliv Rev       Date:  2013-09-10       Impact factor: 15.470

Review 7.  Non-ionic Surfactants as a P-Glycoprotein(P-gp) Efflux Inhibitor for Optimal Drug Delivery-A Concise Outlook.

Authors:  Sachin Rathod; Heta Desai; Rahul Patil; Jayant Sarolia
Journal:  AAPS PharmSciTech       Date:  2022-01-18       Impact factor: 3.246

8.  Intravenous microemulsion of docetaxel containing an anti-tumor synergistic ingredient (Brucea javanica oil): formulation and pharmacokinetics.

Authors:  Shilin Ma; Fen Chen; Xiaohui Ye; Yingjie Dong; Yingna Xue; Heming Xu; Wenji Zhang; Shuangshuang Song; Li Ai; Naixian Zhang; Weisan Pan
Journal:  Int J Nanomedicine       Date:  2013-10-25

9.  Thermoresponsive GenisteinNLC-dexamethasone-moxifloxacin multi drug delivery system in lens capsule bag to prevent complications after cataract surgery.

Authors:  Tingyu Yan; Zhongxu Ma; Jingjing Liu; Na Yin; Shizhen Lei; Xinxin Zhang; Xuedong Li; Yu Zhang; Jun Kong
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

10.  Liquid Chromatographic Method for Irinotecan Estimation: Screening of P-gp Modulators.

Authors:  M Tariq; L M Negi; Sushama Talegaonkar; F J Ahmad; Zeenat Iqbal; A M Khan
Journal:  Indian J Pharm Sci       Date:  2015 Jan-Feb       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.